Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
85.6M
-
Number of holders
-
63
-
Total 13F shares, excl. options
-
38.7M
-
Shares change
-
-964K
-
Total reported value, excl. options
-
$153M
-
Value change
-
-$3.46M
-
Put/Call ratio
-
0.02
-
Number of buys
-
24
-
Number of sells
-
-31
-
Price
-
$3.95
Significant Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) as of Q3 2023
74 filings reported holding LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2023.
Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) has 63 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.7M shares
of 85.6M outstanding shares and own 45.24% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (16.9M shares), CHI Advisors LLC (3.41M shares), Verition Fund Management LLC (2.9M shares), JANUS HENDERSON GROUP PLC (2.46M shares), BlackRock Inc. (1.51M shares), VANGUARD GROUP INC (1.43M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.18M shares), CITADEL ADVISORS LLC (979K shares), Opaleye Management Inc. (849K shares), and MANGROVE PARTNERS (806K shares).
This table shows the top 63 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.